Servier Acquires Day One Biopharmaceuticals to Enhance Oncology Portfolio for Rare Cancers Servier has finalized an acquisition of Day One Biopharmaceuticals, strengthening its oncology pipeline for rare cancers and emphasizing innovation in treatment.

Servier Acquires Day One Biopharmaceuticals to Enhance Oncology Portfolio for Rare Cancers #France #oncology #Day_One_Biopharmaceuticals #Servier #Suresnes

Servier Acquires Day One Biopharmaceuticals to Enhance Rare Oncology Pipeline Servier has officially acquired Day One Biopharmaceuticals, marking a significant expansion of its oncology portfolio, especially in rare cancers.

Servier Acquires Day One Biopharmaceuticals to Enhance Rare Oncology Pipeline #France #oncology #Servier #Suresnes #DAY_ONE

Il ne faut surtout pas priver les actionnaires des sociétés mortifères comme #servier de leurs « petits sous », en assortissant la condamnation d’une confiscation ( sur une information de l’usine nouvelle reprise par @latrombe.bsky.social)

Servier Reports Strong Financial Growth for 2024/25 and Confirms Ambitious 2030 Projections Servier has reported a robust Group revenue of €6.9 billion for 2024/25, showing a 16.2% increase from the previous year and reinforcing its strategic goals for 2030.

Servier Reports Strong Financial Growth for 2024/25 and Confirms Ambitious 2030 Projections #France #oncology #pharmaceuticals #Servier #Suresnes

Servier Reports Strong Performance and Growth Prospects for 2030 Servier has declared impressive financial results for the 2024/25 year, driven by successful oncology sales and a robust pipeline aiming for significant growth by 2030.

Servier Reports Strong Performance and Growth Prospects for 2030 #France #oncology #Neurology #Servier #Suresnes

Servier's Impressive Growth in 2024/25 Reinforces Future Goals for 2030 Servier reports a remarkable 16.2% revenue increase for 2024/25, driven by oncology sales, highlighting its commitment to innovative patient solutions by 2030.

Servier's Impressive Growth in 2024/25 Reinforces Future Goals for 2030 #France #oncology #pharmaceuticals #Servier #Suresnes

⚡️ #Allogene, sous-licencié de #Servier

En vertu de l'accord conclu avec Servier, #Cellectis peut prétendre à un montant maximal de 340 millions de dollars au titre des étapes de développement et de commercialisation, ainsi qu'à des redevances à deux chiffres sur les ventes.

Servier signs €1bn-plus AI pact with Iktos In its second AI-focused drug discovery deal in the space of a week, Servier has announced a €1bn partnership with France's Iktos.

#drugdiscovery #Servier #Iktos #Chemspeed #roboticspoweredchemistryplatform #smallmoleculetherapies #generativeAI #PharmaAIdrugdiscoveryplatform #smallmoleculedrugdiscovery #AIorchestrateddiscovery
#translationalscience #smallmoleculetherapeutics #AIindrugdiscovery #RandD
zurl.co/L8opQ

Now Iktos teams up with Pierre Fabre in oncology As Servier announces its partnership with Paris, France-based Iktos, now Pierre Fabre Laboratories has revealed an integrated collaboration with Iktos

In the same week that #Servier announced its partnership with Paris, France-based #Iktos, now #PierreFabreLaboratories has revealed an integrated collaboration with Iktos to identify and develop novel #smallmolecule drug candidates in #oncology.

pharmaphorum.com/news/now-ikt...

En vertu de l'accord conclu avec #Servier, #Cellectis peut prétendre à un montant maximal de 340 millions de dollars au titre des étapes de développement et de commercialisation, ainsi qu'à des redevances à deux chiffres sur les ventes.

#Servier / #Allogene

#CD19 : Allogene, sous-licencié de Servier, a annoncé que l'analyse intermédiaire de futilité de l'essai pivot de phase 2 #ALPHA3 (évaluant cema-cel en consolidation de première ligne pour le #Lymphome à grands cellules B) est confirmée pour le S1 2026.

IktosがServierと形成したAI創薬での戦略的提携について IktosがServierと締結した共同研究契約は、AIを通じたがん治療の新薬開発を加速させる革新的な取り組みです。

IktosがServierと形成したAI創薬での戦略的提携について #Iktos #AI創薬 #Servier

IktosがServierと締結した共同研究契約は、AIを通じたがん治療の新薬開発を加速させる革新的な取り組みです。

Insilico and Servier Strike Up to 888 Million Dollar AI Oncology Drug Discovery Deal - OncoDaily Insilico and Servier Strike Up to 888 Million Dollar AI Oncology Drug Discovery Deal / AI, AI and healthcare, biotech, cancer, Insilico, OncoDaily, OncoDaily

Insilico and Servier Strike Up to 888 Million Dollar AI Oncology Drug Discovery Deal

oncodaily.com/techology/in...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Insilico #Servier

Insilico adds Sanofi to partnership roster with $888m deal Insilico has added to its partnerships list with an $888m cancer-focused alliance with Servier, just days after completing its long-awaited IPO.

Fresh from its IPO at the end of last year, #InsilicoMedicine has added to its stable of partners after signing a new #alliance with #Servier that could be worth up to $888 million.

pharmaphorum.com/news/insilic...

Insilico Medicine Engages in $888 Million Partnership with Servier for Innovative Cancer Therapies Insilico Medicine has formed an $888 million R&D collaboration with Servier, aiming to leverage AI technology for oncology drug development. This partnership will enhance drug discovery processes significantly.

Insilico Medicine Engages in $888 Million Partnership with Servier for Innovative Cancer Therapies #USA #Cambridge #oncology #Insilico_Medicine #Servier

Résultat favorable pour #Servier

Décision arbitraire réaffirme le contrôle d’ #Allogene sur Cema-Cel

La décision confirme la licence d’ #Allo sur les droits de l’ #UE et #UK, avec des options pour le #Japon et la #Chine, ouvrant l’obtention de droits mondiaux

ir.allogene.com/news-release...

🧬 #Cellectis annonce une décision arbitrelle en litige avec #Servier
Résiliation partielle de l’accord de licence concernant #UCART19_V1 (également appelé « #ALLO_501 » par #Allogene)
Toutes les autres réclamations déposées par les parties ont été rejetées.
www.cellectis.com/en/press/cel...

Servier’s Voranigo® (Vorasidenib) Wins Multiple Prix Galien Awards for Rare Diseases Voranigo®, developed by Servier, has won several esteemed Prix Galien Awards, recognizing its advancements for patients with gliomas.

Servier’s Voranigo® (Vorasidenib) Wins Multiple Prix Galien Awards for Rare Diseases #France #Servier #Suresnes #Prix_Galien #Voranigo®

Servier's Voranigo® Achieves Multiple Prix Galien Awards for Glioma Treatment Voranigo® has received prestigious Prix Galien Awards in the USA, Poland, and for Bridges, recognizing its impact on patients with glioma.

Servier's Voranigo® Achieves Multiple Prix Galien Awards for Glioma Treatment #France #Servier #Suresnes #VORANIGO #Prix_Galien

💥 Ne pas oublier…

Il y a moins de 5 ans, #Cellectis valait 28 €

Aujourd’hui autour de 3,40 €, alors que :

⚖️ Arbitrage #Servier (jusqu’à 1,41 Md$ théorique)
🧬 Données #UCART à l’ #ASH25
🤝 Partenaire #AstraZeneca
📚 Publication dans #Nature
💶 Tréso jusqu’en 2027

💥 Scénario post-arbitrage maximaliste pour #Cellectis vs #Servier
⚖️ Cellectis réclame :
🔹 410 M$ de jalons non versés
🔹 Plus jusqu’à 1 Md$ de royalties futures
➡️ Total théorique : ~1,41 Md$
📈 Si l’intégralité était octroyée → Valorisation post-arbitrage ≈ 15,50 €/action (vs 3,40 €)

Servier Showcases Leadership in Research at 2025 SNO Congress on IDH-Mutant Gliomas At the SNO Congress, Servier presents critical findings from studies focusing on IDH-mutant gliomas, highlighting advancements in cancer treatment and trial methodologies.

Servier Showcases Leadership in Research at 2025 SNO Congress on IDH-Mutant Gliomas #United_States #IDH-mutant_glioma #Honolulu #Servier #VORANIGO

Servier's Commitment to Hematology Showcased at 67th ASH Annual Meeting Servier's participation at the 67th ASH Annual Meeting highlights new data in hematology, particularly focusing on AML and MDS treatments with TIBSOVO.

Servier's Commitment to Hematology Showcased at 67th ASH Annual Meeting #USA #Orlando #Hematology #Servier #Tibsovo

Servier Pharmaceuticals Honored with 2025 Prix Galien USA Servier Pharmaceuticals Honored with 2025 Prix Galien USA Award / cancer, Glioma Therapy, Headlines, IDH-mutant glioma, OncoDaily, Oncology, Prix Galien USA

Servier Pharmaceuticals Honored with 2025 Prix Galien USA Award

oncodaily.com/insight/serv...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Servier

Servier's VORANIGO® Triumphs at 2025 Prix Galien USA Award Ceremony Servier's VORANIGO® (vorasidenib) has won the prestigious 2025 Prix Galien USA Award, recognizing its groundbreaking treatment for glioma patients.

Servier's VORANIGO® Triumphs at 2025 Prix Galien USA Award Ceremony #USA #New_York #Servier #Glioma #VORANIGO

#JeremyFerrari

Rappel
#Servier
#Defiscalisation
#Sarkozy

Servier, Emilio Gagliardi nuovo presidente in Italia (Adnkronos) - Da ottobre Emilio Gagliardi è il nuovo presidente del gruppo Servier in Italia, una tra le affiliate più importanti della multinazionale francese (quarta per fatturato a livello globale e prima in Europa), che da ottobre...

Servier, Emilio Gagliardi nuovo presidente in Italia ... LEGGI TUTTO #Servier #EmilioGagliardi #presidente #Italia #multinazionale

European Commission Approves VORANIGO® as the First Therapy for IDH-Mutant Glioma in Adults The European Commission has approved VORANIGO® as the first targeted treatment for Grade 2 IDH-mutant glioma, marking a breakthrough in precision medicine for this condition.

European Commission Approves VORANIGO® as the First Therapy for IDH-Mutant Glioma in Adults #None #Servier #Glioma #VORANIGO

Original post on cheezburger.com

'A string of cheese was still hanging from my mouth to the plate': 18+ Servers share their most unhinged, jaw-dropping workplace stories Now and then, a waitress will spill a drink or the h...

#customer #service #shift #workplace-stories #hotel #hospitality […]

[Original post on cheezburger.com]

Servier bets $450m on Fragile X syndrome drug Servier has pushed its emerging neurology pipeline into the clinical trials stage by licensing a drug for Fragile X syndrome from the UK's Kaerus.

#biotech #Servier #FragileXsyndrome #FXS #rarediseases #KaerusBioscience #FRAXAResearchFoundation #FXStherapies #orphandrug #rarepaediatricdrugdesignation #FDA #neurodevelopmentaldisorder #raremovementdisorder #lifesciencesventurecapital #Medicxi #BKchannelmodulatorprogramme
zurl.co/EPSas